Literature DB >> 10944516

Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators.

Y Kodera1, K Takeyama, A Murayama, M Suzawa, Y Masuhiro, S Kato.   

Abstract

The nuclear peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor superfamily and acts as a ligand-dependent transcription factor mediating adipocyte differentiation, cell proliferation and inflammatory processes, and modulation of insulin sensitivity. Members of the 160-kDa protein (SRC-1/TIF2/AIB-1) family of coactivators, CBP/p300 and TRAP220/DRIP205, are shown to interact directly with PPARgamma and potentiate nuclear receptor transactivation function in a ligand-dependent fashion. Because PPARgamma ligands exert partially overlapping but distinct subsets of biological action through PPARgamma binding, we wished to examine whether interactions between PPARgamma and known coactivators were induced to the same extent by different classes of PPARgamma ligand. The natural ligand 15-deoxy-Delta12,14-prostaglandin J(2) induced PPARgamma interactions with all coactivators tested (SRC-1, TIF2, AIB-1, p300, TRAP220/DRIP205) in yeast and mammalian two-hybrid assays, as well as in a glutathione S-transferase pull-down assay. However, under the same conditions troglitazone, a synthetic PPARgamma ligand that acts as an antidiabetic agent, did not induce PPARgamma interactions with any of the coactivators. Our findings suggest that ligand binding may alter PPARgamma structure in a ligand type-specific way, resulting in distinct PPARgamma-coactivator interactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944516     DOI: 10.1074/jbc.C000517200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

2.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

Review 3.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

4.  Two butenolides with PPARα agonistic activity from a marine-derived Streptomyces.

Authors:  Yasuhiro Igarashi; Marumi Ikeda; Satoshi Miyanaga; Hiroaki Kasai; Yoshikazu Shizuri; Nobuyasu Matsuura
Journal:  J Antibiot (Tokyo)       Date:  2014-11-12       Impact factor: 2.649

5.  Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation.

Authors:  Anne-M Krogsdam; Curt A F Nielsen; Søren Neve; Dorte Holst; Torben Helledie; Bo Thomsen; Christian Bendixen; Susanne Mandrup; Karsten Kristiansen
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

6.  Vitamin B6 regulates mRNA expression of peroxisome proliferator-activated receptor-γ target genes.

Authors:  Noriyuki Yanaka; Mayumi Kanda; Keigo Toya; Haruna Suehiro; Norihisa Kato
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

7.  PPARγ inhibits airway epithelial cell inflammatory response through a MUC1-dependent mechanism.

Authors:  Yong Sung Park; Erik P Lillehoj; Kosuke Kato; Choon Sik Park; Kwang Chul Kim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-20       Impact factor: 5.464

8.  15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway.

Authors:  Nirmal K Phulwani; Douglas L Feinstein; Vitaliy Gavrilyuk; Candan Akar; Tammy Kielian
Journal:  J Neurochem       Date:  2006-12       Impact factor: 5.372

Review 9.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

10.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.